COMMUNIQUÉS West-GlobeNewswire

Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial
24/02/2025
As presented at ARO, 10 of 11 children with at least one post-treatment assessment showed notable improvements in hearing Speech and development progress followed dramatic improvements in hearing in first child treated [...]
AEON Biopharma, Inc. Announces Reverse Stock Split
24/02/2025
IRVINE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar [...]
SRx Health Solutions Shareholders Unanimously Approve Acquisition by Better Choice Company
24/02/2025
TAMPA, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Better Choice Company, Inc. (NYSE American: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, announced today that SRx Health Solutions, Inc. (“ [...]
Compass Health announces the Marc Healing Center as name of state-of-the-art regional facility for intensive behavioral health services
24/02/2025
The Marc Healing Center is Phase II of Compass Health’s three-phase Broadway Campus Redevelopment, designed to advance whole person health in Northwest Washington EVERETT, Wash., Feb. 24, 2025 (GLOBE NEWSWIRE) -- On [...]
Harvard Bioscience Schedules Fourth Quarter 2024 Earnings Conference Call for March 12, 2025 at 8:00 AM ET
24/02/2025
HOLLISTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2024, before the market opens on March 12, 2025, and [...]
United States FDA Approves NM8074 (Ruxoprubart) IND for Treating Dermatomyositis (DM): A Chronic Inflammatory Disorder of the Skin
24/02/2025
--- The United States FDA Approves the Initiation for Phase II Efficacy Trial in Dermatomyositis ( DM ) Patients: A Skin & Muscle Disorder DM is an immune-mediated myopathy characterized by chronic inflammation of [...]
OrganOx Completes $142 Million Equity Financing Led by HealthQuest Capital
24/02/2025
Financing strengthens OrganOx to expand its leadership position in organ technology OXFORD, United Kingdom and MADISON, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- OrganOx Ltd ., a leading organ medical technology company, [...]
SYNERGIA MEDICAL ANNOUNCES STRONG RESULTS FOR NAO.VNS™ FIRST-IN-HUMAN STUDY
24/02/2025
Primary safety endpoint met - No serious adverse events reported over 3-months Robust device performance - No device failure reported over 3-months Synergia Medical announces that its NAO.VNS™ device, successfully [...]
WW International, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call
24/02/2025
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers,” “WW,” or the “Company”) will release its results for the fourth quarter and full year 2024 ended December 28, 2024, [...]
Bright Green Corporation Announces the completion of its restructuring plan, withdraws from the Cannabis business and sets course on the production of all DEA Scheduled Controlled Substances
24/02/2025
FORT LAUDERDALE, FLORIDA, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC: BGXX) (“Bright Green” or the “Company”) announced that on February 24, 2025, on behalf of the Company, Lynn Stockwell has asked [...]
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference
24/02/2025
REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in a fireside chat presentation at the 45th Annual TD [...]
IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference
23/02/2025
• Findings support the development of a novel peptide vaccine targeting the immunosuppressive effects of Transforming Growth Beta (TGF- β ) in solid tumors NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq [...]
Bay Area Therapy Center Offers Specialized Therapy for Overcoming Communication and Relationship Issues in San Francisco
23/02/2025
Offering Expert Therapy Services in San Francisco, the Center Provides Tailored Solutions for Jealousy, Attachment, and More SAN FRANCISCO, Feb. 23, 2025 (GLOBE NEWSWIRE) -- Bay Area Therapy Center is excited to [...]
Hospital shooting highlights the dangers and violence nurses often face at work
23/02/2025
One in four nurses face workplace violence, a rate higher than police and correctional officers. SILVER SPRING, MD, Feb. 22, 2025 (GLOBE NEWSWIRE) -- SILVER SPRING, MD – The American Nurses Association (the association [...]
Bay Area Cognitive Behavioral Therapy Center Expands Treatment Offerings with Acceptance and Commitment Therapy
22/02/2025
Bay Area Therapy Center Expand Treatment Options Offering Comprehensive Mental Health Services in San Francisco SAN FRANCISCO, Feb. 22, 2025 (GLOBE NEWSWIRE) -- The Bay Area Cognitive Behavioral Therapy Center , a [...]
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
22/02/2025
ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre- [...]
Communiqué de presse : ECCO 2025 : de nouvelles données sur le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de la maladie de Crohn
22/02/2025
ECCO 2025 : de nouvelles données sur le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de la maladie de Crohn De nouvelles données détaillées de l’ [...]
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
22/02/2025
Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different [...]
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
21/02/2025
SAN CARLOS, Calif., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal [...]

Pages